1.1-1.3 | Objective, regulatory applicability and scope of the guide | 0 |
1.3-start | Designate and justify the point at which API production begins (the API starting material) and apply GMP from that step onward, with stringency rising towards final steps | 0 |
10.1-10.2 | Store materials under recorded appropriate conditions with segregated quarantine, rejected, returned and recalled stock, distribute only quality-released product, control transport | 0 |
11.1 | Give the quality unit adequate laboratories, documented sampling and test procedures, scientifically sound quality-approved specifications consistent with the filing, OOS investiga | 0 |
11.2 | Test each batch of intermediate and API for conformance, establish and periodically compare an impurity profile for each API, and run microbiological tests where microbial quality | 0 |
11.4 | Issue authentic, signed certificates of analysis on request that show the product, batch, release date, dating, each test with limits and numerical results, and the original manufa | 0 |
11.5 | Run a documented, ongoing stability programme with validated stability-indicating methods to confirm storage conditions and retest or expiry dates | 0 |
11.6 | Base API expiry or retest dates on stability data (pilot batches allowed for preliminary dates when representative) and support dating of intermediates shipped outside the company | 0 |
11.7 | Retain identified reserve samples of each API batch for the required period, in equivalent or more protective packaging and in enough quantity for two full analyses | 0 |
12.1-12.2 | Document a validation policy, identify critical parameters and attributes, and validate critical operations under quality-approved protocols and reports that address deviations | 0 |
12.3 | Complete design, installation, operational and performance qualification of critical equipment and ancillary systems before process validation | 0 |
12.4-12.5 | Validate API processes, normally prospectively before commercial distribution of the medicine, using concurrent or retrospective approaches only where their conditions are met, wit | 0 |
12.6 | Periodically evaluate validated systems and processes to confirm they remain in a validated state | 0 |
12.7 | Validate cleaning procedures where carry-over poses the greatest risk, with representative worst-case selection, a full protocol, suitable sampling and validated sensitive methods, | 0 |
12.8 | Validate analytical methods (or verify compendial ones under actual use) per the ICH validation guidelines, qualify analytical equipment first and record any method modification wi | 0 |
13 | Operate a formal change control system: quality unit approval, impact evaluation and classification, document updates, evaluation of first batches, stability impact and notificatio | 0 |
14.1-14.2 | Quarantine and record the disposition of out-of-specification material, and reprocess only by repeating established steps, building routine reprocessing into the process and evalua | 0 |
14.3 | Investigate non-conformance before reworking, then show reworked batches are of equivalent quality by evaluation, testing, stability where warranted and impurity profile comparison | 0 |
14.4 | Recover reactants, intermediates, APIs and solvents only under approved, controlled and monitored procedures with documented use and proven suitability | 0 |
14.5 | Quarantine returned intermediates and APIs, reprocess, rework or destroy them where storage or container condition casts doubt, and record each return | 0 |
15 | Record and investigate all quality complaints under a written procedure, trend them, keep a recall procedure, and inform authorities in serious or life-threatening situations | 0 |
16 | Evaluate contract manufacturers and laboratories for GMP, set written GMP responsibilities with audit rights, control subcontracting and changes, and keep records at the contract s | 0 |
17.1-17.3 | Agents, brokers, traders, distributors, repackers and relabellers comply with GMP, operate a quality system and keep complete traceability documents for every API and intermediate | 0 |
17.4-17.5 | Repack, relabel and hold APIs under GMP controls and suitable environmental conditions, and run stability studies when repacking into a different container type | 0 |
17.6 | Pass all quality and regulatory information between the manufacturer and the customer, name the original manufacturer and batch, disclose the manufacturer to authorities on request | 0 |
17.7-17.8 | Distributors and repackers record complaints and recalls, review them with the original manufacturer where warranted, keep the manufacturer's responses, and handle and document ret | 0 |
18.1 | Control every stage of cell culture and fermentation APIs: appropriate prior steps, environmental controls matched to open or closed processing, process controls for cell banks, cu | 0 |
18.1-intro | Section 18 general: specific guidance for APIs made by cell culture or fermentation | 0 |
18.2 | Restrict access to cell banks, store them to keep viability and prevent contamination, record vial use and storage and monitor suitability | 0 |
18.3 | Use closed systems or controlled environments for aseptic additions and open manipulations, monitor critical culture parameters, clean and sterilise equipment and media, and detect | 0 |
18.4 | Harvest and purify in equipment and areas that minimise contamination, with procedures that consistently remove the organism, debris and media, clean equipment after use and add co | 0 |
18.5 | Run viral removal and inactivation steps within validated parameters and prevent virus carry-over by segregation, separate air handling and cleaning | 0 |
19.1-19.3 | Manufacture clinical trial APIs in suitable facilities with stage-appropriate GMP, an independent quality unit approving each batch, material testing, problem evaluation, investiga | 0 |
19.1-intro | Section 19 general: APIs for use in clinical trials | 0 |
19.4-19.5 | Evaluate raw materials for clinical APIs by testing or supplier analysis with identity testing, and document production in notebooks or batch records | 0 |
19.6-19.7 | Validate processes per section 12 once batches are for commercial use, even at pilot scale, and record every change to production, specifications or test procedures during developm | 0 |
19.8-19.9 | Use scientifically sound methods for clinical batches, retain reserve samples and records for an appropriate period after the application ends, apply dating rules to existing APIs | 0 |
2.1 | Run an effective, documented quality management system with management involvement and an independent quality unit covering both QA and QC | 0 |
2.2 | Keep the quality unit involved in every quality matter and assign it, in writing and without delegation, the core release, approval and oversight responsibilities | 0 |
2.3 | Define production's responsibilities in writing, from approved instructions and completed batch records to deviation reporting, clean facilities, calibration, maintenance and quali | 0 |
2.4 | Perform scheduled internal audits (self-inspections) of GMP compliance, report findings to management and close corrective actions on time | 0 |
2.5 | Conduct and document a product quality review of each API, normally every year, and act on what it shows | 0 |
20 | Section 20: glossary of terms | 0 |
3.1 | Staff manufacture with enough qualified people, written responsibilities and regular, recorded, periodically assessed GMP training | 0 |
3.2 | Enforce personnel hygiene: suitable clean clothing and protective wear, no direct contact with product, food and smoking kept to set areas, and exclusion of ill workers | 0 |
3.3 | Use only suitably qualified consultants and keep records of their name, address, qualifications and service | 0 |
4.1 | Design buildings and material and people flows to ease cleaning and maintenance, prevent mix-ups and contamination, and provide defined areas for each activity | 0 |
4.2 | Qualify and monitor utilities that can affect product (steam, gases, compressed air, HVAC), control air handling and recirculation, identify pipework and protect drains | 0 |
4.3 | Show process water is fit for use (at least drinking-water quality unless justified), set tighter specifications where needed and validate any in-house treatment | 0 |
4.4 | Use dedicated production areas for highly sensitising materials such as penicillins and cephalosporins, consider them for highly potent or infectious materials, and keep toxic non- | 0 |
4.5-4.6 | Provide adequate lighting in all areas and dispose of sewage, refuse and process waste safely, promptly and hygienically in identified containers | 0 |
4.7 | Keep buildings maintained, repaired and clean under written sanitation procedures, including controlled use of pest control agents and cleaning chemicals | 0 |
5.1 | Design, build, identify and use process equipment so it suits its purpose, does not alter product, stays within its qualified range and has current drawings | 0 |
5.2 | Maintain equipment preventively and clean it under detailed written procedures with justified residue limits, status labelling and controls against carry-over | 0 |
5.3 | Calibrate critical control, weighing, measuring, monitoring and test equipment to a written schedule against traceable standards, and investigate out-of-calibration findings | 0 |
5.4 | Validate GMP computerised systems and control access, data changes, data entry, incidents, changes, backup and data protection | 0 |
6.1 | Control GMP documents through their life cycle, specify retention periods and keep production, control and distribution records for the minimum times | 0 |
6.2 | Keep equipment use, cleaning, sanitisation, sterilisation and maintenance logs that identify the date, product, batch and person | 0 |
6.3 | Record receipt, testing, use and disposition of raw materials, intermediates, labels and packaging materials, and keep master labels for comparison | 0 |
6.4 | Prepare master production instructions for each intermediate and API, signed by one person and independently checked and signed by the quality unit, with the full content set | 0 |
6.5 | Issue a checked, uniquely numbered batch production record for each batch, document each significant step, and investigate critical deviations and failures across related batches | 0 |
6.6 | Keep complete laboratory control records: samples, methods, weights, raw data, calculations, results against criteria, analyst signature and second-person review | 0 |
6.7 | Review and approve batch production and laboratory records, including all deviation, investigation and OOS reports, before release; the quality unit reviews critical steps | 0 |
7.1 | Govern materials under written procedures and buy critical materials against agreed specifications from quality-approved suppliers whose actual manufacturer is known | 0 |
7.2 | Inspect each incoming container, quarantine materials until released, prevent wrong discharge into existing stock, assure tanker cleanliness and give every lot a distinctive code a | 0 |
7.3 | Test at least identity on each incoming batch, rely on supplier certificates only after supplier qualification with periodic full testing, justify exemptions and sample representat | 0 |
7.4-7.5 | Store materials to prevent degradation and contamination, off the floor, oldest first, with rejected stock quarantined, and re-evaluate materials after prolonged storage or exposur | 0 |
8.1 | Weigh and subdivide materials accurately into identified containers, witness critical operations, compare actual and expected yields, investigate deviations and show equipment proc | 0 |
8.2 | Meet time limits set in the master instructions, document and evaluate deviations, and hold intermediates under suitable conditions | 0 |
8.3 | Define and approve in-process controls and sampling procedures, record all results in the batch record and protect in-process sample integrity | 0 |
8.4 | Blend only batches that individually meet specification, never to rescue out-of-specification batches; control, document, trace, validate where attributes are critical and date by | 0 |
8.5 | Control carry-over of residues between successive batches and prevent contamination of intermediates and APIs, especially after purification | 0 |
9.1-9.2 | Control receipt, testing and release of packaging and labelling materials, reject non-conforming ones, and use clean, non-reactive containers that protect the product | 0 |
9.3 | Restrict access to labels, reconcile labels issued, used and returned, destroy excess and obsolete labels, control printing devices and keep a representative label in the batch rec | 0 |
9.4 | Run packaging and labelling to prevent mix-ups, label containers with the required identity, batch, storage, manufacturer and dating information, line-clear before use, check label | 0 |